TQB-3234 is under clinical development by Sino Biopharmaceutical and currently in Phase I for Thyroid Cancer. According to GlobalData, Phase I drugs for Thyroid Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TQB-3234’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TQB-3234 overview

TQB-3234 is under development for the treatment of melanoma, colorectal cancer, pancreatic cancer, thyroid cancer, neurofibromatosis (NF1) related neurofibromatosis and peripheral malignant nerve sheath tumors. The drug candidate is administered through the oral route. It acts by targeting MEK1/2 kinases. It was also under development for lung cancer.

Sino Biopharmaceutical overview

Sino Biopharmaceutical (Sino Biopharma), a subsidiary of Charoen Pokphand Group, is a research-oriented pharmaceutical company that develops, manufactures, and markets medicines, biopharmaceuticals, and Chinese medicines. It offers medicines for the treatment of hepatitis, cardio-cerebral diseases, cancer, orthopedic conditions, infectious diseases, and respiratory and digestive diseases, among others. The company offers products in various dosage forms including large-volume injections, PVC-free soft bags for intravenous injections, small-volume injections, powdered medicines, granulated medicines, capsules, and tablets. It works in partnership with several domestic and foreign pharmaceutical companies to advance the development of its products. Sino Biopharma is headquartered in Beijing, China.

For a complete picture of TQB-3234’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.